Pregled bibliografske jedinice broj: 1034739
Bioactive Sphingolipids as Biomarkers Predictive of Disease Severity and Treatment Response in Cancer: Current Status and Translational Challenges
Bioactive Sphingolipids as Biomarkers Predictive of Disease Severity and Treatment Response in Cancer: Current Status and Translational Challenges // Anticancer research, 39 (2019), 1; 41-56 doi:10.21873/anticanres.13078 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1034739 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Bioactive Sphingolipids as Biomarkers
Predictive of Disease Severity and Treatment
Response in Cancer: Current Status and
Translational Challenges
Autori
Sedić, Mirela ; Grbčić, Petra ; Kraljević Pavelić, Sandra
Izvornik
Anticancer research (0250-7005) 39
(2019), 1;
41-56
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Ceramide ; biomarker ; cancer ; diagnosis ; review ; sphingosine-1-phosphate ; treatment response
Sažetak
Recent translational studies in cancer have produced a wealth of evidence to support an association between sphingolipid metabolism and clinical outcomes, which underscores the clinical importance of sphingolipid-related biomarkers in cancer diagnosis and prognosis. Importantly, circulating levels of bioactive sphingolipids were demonstrated to correlate with patient survival and treatment response in different tumour types, which could provide novel non-invasive cancer biomarkers. Here, we give a comprehensive overview of recent findings on bioactive sphingolipid species and protein regulators of their metabolism and signalling as novel potential biomarkers for risk assessment, prevention and prediction of treatment response in several types of solid cancers, including prostate, liver, pancreatic, breast and colon cancer, head and neck squamous cell carcinoma and gliomas. Finally, we critically discuss current issues in clinical translation of sphingolipid biomarkers and give our perspective on how these problems could be handled to facilitate implementation of sphingolipid-based diagnostics into clinical practice.
Izvorni jezik
Engleski
POVEZANOST RADA
Projekti:
uniri-biomed-18-76 1209
uniri-biomed-18-133
HRZZ-IP-2018-01-3900 - Rasvijetljavanje mehanizama rezistencije na terapiju raka debelog crijeva sa mutacijom BRAF pomoću integriranog -omics pristupa (BRAFCON) (Sedić, Mirela, HRZZ - 2018-01) ( CroRIS)
Ustanove:
Sveučilište u Rijeci,
Sveučilište u Rijeci - Odjel za biotehnologiju
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- BIOSIS Previews (Biological Abstracts)